Epidemiology, resource use, and treatment patterns of locally advanced or metastatic urothelial carcinoma in France.

IF 2.6 4区医学 Q2 ONCOLOGY Future oncology Pub Date : 2025-03-01 Epub Date: 2025-02-20 DOI:10.1080/14796694.2025.2459058

Florence Joly, Stephane Culine, Morgan Roupret, Aurore Tricotel, Emilie Casarotto, Sandrine Brice, Rafael Minacori, Marthe Vuillet, Marie-Catherine Thomas, Kirsten Leyland, Anil Upadhyay, Vicki Munro, Torsten Strunz-McKendry

{"title":"Epidemiology, resource use, and treatment patterns of locally advanced or metastatic urothelial carcinoma in France.","authors":"Florence Joly, Stephane Culine, Morgan Roupret, Aurore Tricotel, Emilie Casarotto, Sandrine Brice, Rafael Minacori, Marthe Vuillet, Marie-Catherine Thomas, Kirsten Leyland, Anil Upadhyay, Vicki Munro, Torsten Strunz-McKendry","doi":"10.1080/14796694.2025.2459058","DOIUrl":null,"url":null,"abstract":"Aim: Describe real-world epidemiology, treatment patterns, health care resource utilization, and costs of locally advanced or metastatic urothelial carcinoma (la/mUC) in France.Patients & methods: Retrospective study including all adults with la/mUC diagnosis during January 2017 to December 2020 in the PMSI database.Results: Annual prevalence and incidence ranged from 36.4 to 38.9 and 16.4 to 18.5 cases per 100,000 people, respectively. Of the 25,314 patients with incident la/mUC, 37.6% did not receive first-line systemic treatment. Of the 14,656 patients who started first-line systemic treatment, 66.6%, 22.5%, and 10.9% received 1, 2, and 3 lines of therapy, respectively. Annual per-patient costs in second-/third-line setting ranged from €8803 to €16,012.Conclusion: The substantial disease burden of la/mUC in France highlights the unmet need for new therapies.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"665-679"},"PeriodicalIF":2.6000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11881851/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14796694.2025.2459058","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/20 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Aim: Describe real-world epidemiology, treatment patterns, health care resource utilization, and costs of locally advanced or metastatic urothelial carcinoma (la/mUC) in France.

Patients & methods: Retrospective study including all adults with la/mUC diagnosis during January 2017 to December 2020 in the PMSI database.

Results: Annual prevalence and incidence ranged from 36.4 to 38.9 and 16.4 to 18.5 cases per 100,000 people, respectively. Of the 25,314 patients with incident la/mUC, 37.6% did not receive first-line systemic treatment. Of the 14,656 patients who started first-line systemic treatment, 66.6%, 22.5%, and 10.9% received 1, 2, and 3 lines of therapy, respectively. Annual per-patient costs in second-/third-line setting ranged from €8803 to €16,012.

Conclusion: The substantial disease burden of la/mUC in France highlights the unmet need for new therapies.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

法国局部晚期或转移性尿路上皮癌的流行病学、资源利用和治疗模式。

目的：描述法国局部晚期或转移性尿路上皮癌（la/mUC）的现实世界流行病学、治疗模式、卫生保健资源利用和成本。患者和方法：回顾性研究包括2017年1月至2020年12月PMSI数据库中诊断为la/mUC的所有成年人。结果：年患病率和发病率分别为每10万人36.4 ~ 38.9例和16.4 ~ 18.5例。在25314例la/mUC患者中，37.6%没有接受一线全身治疗。在14,656名开始一线全身治疗的患者中，66.6%、22.5%和10.9%分别接受了1线、2线和3线治疗。在二线/三线治疗中，每位患者的年费用从8803欧元到16012欧元不等。结论：法国la/mUC的巨大疾病负担突出了对新疗法的需求未得到满足。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Future oncology ONCOLOGY-

CiteScore

5.40

自引率

3.00%

发文量

335

审稿时长

4-8 weeks

期刊介绍： Future Oncology (ISSN 1479-6694) provides a forum for a new era of cancer care. The journal focuses on the most important advances and highlights their relevance in the clinical setting. Furthermore, Future Oncology delivers essential information in concise, at-a-glance article formats - vital in delivering information to an increasingly time-constrained community. The journal takes a forward-looking stance toward the scientific and clinical issues, together with the economic and policy issues that confront us in this new era of cancer care. The journal includes literature awareness such as the latest developments in radiotherapy and immunotherapy, concise commentary and analysis, and full review articles all of which provide key findings, translational to the clinical setting.